Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography
- PMID: 35753356
- PMCID: PMC9336200
- DOI: 10.1016/j.ahj.2022.06.004
Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography
Abstract
Background: Inflammation, measured by traditional biomarkers such as C-reactive protein, has been linked to cardiovascular (CV) events. Recent technological advancement has allowed for measuring larger numbers of inflammatory biomarkers. A contemporary evaluation with established and novel biomarkers of inflammation is needed.
Methods: 1,090 individuals who underwent coronary angiography were enrolled. Twenty-four inflammatory biomarkers were collected prior to angiography. Unsupervised machine learning cluster analyses determined unique patterns of inflammatory biomarkers. Cox proportional hazard regression assessed both association of inflammatory biomarker clusters and individual biomarker associations with major adverse cardiovascular events (MACE; non-fatal myocardial infarction or stroke, and CV death) during a median follow-up of 3.67 years.
Results: Four distinct clusters were recognized. Incremental increases in inflammatory biomarkers were observed from cluster 1 to cluster 4. During follow-up, 263 MACE were ascertained. Considering cluster 1 as a reference, study participants with inflammatory cluster 2 (Hazard ratio [HR] 1.55, 95% confidence interval [CI]: 1.01-2.37), cluster 3 (HR 1.89, CI: 1.25-2.85), and cluster 4 (HR 2.93, CI: 1.95-4.42) were at increased risk of MACE. Interleukin (IL)-1α IL-6, IL-8, IL-10, IL-12, Adhesion molecule-1 high-sensitivity C-reactive protein, ferritin, myeloperoxidase, macrophage inflammatory protein (MIP)-1a, MIP 3, and macrophage colony-stimulating factor-1 were independently associated with MACE.
Conclusions: Among persons undergoing coronary angiography procedures, distinct clusters of inflammatory biomarker distributions with significant prognostic meaning may be identified. These results may identify unique targets for anti-inflammatory treatments aimed at CV disease.
Copyright © 2022 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status.Am J Cardiol. 2013 Feb 15;111(4):465-70. doi: 10.1016/j.amjcard.2012.10.027. Epub 2012 Dec 4. Am J Cardiol. 2013. PMID: 23219176 Free PMC article.
-
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.JAMA Cardiol. 2021 Dec 1;6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079. JAMA Cardiol. 2021. PMID: 34431970 Free PMC article. Clinical Trial.
-
GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.Am Heart J. 2018 Aug;202:27-32. doi: 10.1016/j.ahj.2018.04.003. Epub 2018 Apr 6. Am Heart J. 2018. PMID: 29803983
-
Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.Clin Cardiol. 2012 Aug;35(8):482-9. doi: 10.1002/clc.21988. Epub 2012 Apr 9. Clin Cardiol. 2012. PMID: 22488248 Free PMC article.
-
Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infrared Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing Coronary Angiography (ATHEROREMO-NIRS Substudy).Curr Atheroscler Rep. 2018 Sep 14;20(10):52. doi: 10.1007/s11883-018-0752-8. Curr Atheroscler Rep. 2018. PMID: 30218437 Free PMC article. Review.
Cited by
-
Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk.J Am Heart Assoc. 2024 Jan 16;13(2):e031646. doi: 10.1161/JAHA.123.031646. Epub 2024 Jan 12. J Am Heart Assoc. 2024. PMID: 38214281 Free PMC article.
-
Serum IL-38 Level Was Associated with Incidence of MACE in the STEMI Patients.Int J Gen Med. 2023 Jul 12;16:2987-2997. doi: 10.2147/IJGM.S417471. eCollection 2023. Int J Gen Med. 2023. PMID: 37465556 Free PMC article.
-
Advances in the study of S100A9 in cardiovascular diseases.Cell Prolif. 2024 Aug;57(8):e13636. doi: 10.1111/cpr.13636. Epub 2024 Mar 19. Cell Prolif. 2024. PMID: 38504474 Free PMC article. Review.
-
Inflammatory Biomarkers to Predict Major Adverse Cardiovascular Events in Patients with Carotid Artery Stenosis.Medicina (Kaunas). 2024 Jun 18;60(6):997. doi: 10.3390/medicina60060997. Medicina (Kaunas). 2024. PMID: 38929614 Free PMC article.
-
The role of early-phase trials and real-world evidence in drug development.Nat Cardiovasc Res. 2024 Feb;3(2):110-117. doi: 10.1038/s44161-024-00420-4. Epub 2024 Feb 15. Nat Cardiovasc Res. 2024. PMID: 39196202 Review.
References
-
- Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969–979. - PubMed
-
- Guedeney P, Claessen BE, Kalkman DN, et al. Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2019;73:2401–2409. - PubMed
-
- Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42:113–131. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials